Search clinical trials for: UMEC/VI

Total 179 results

GlaxoSmithKline

Completed

Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study.

Pulmonary Disease, Chronic Obstructive

China
GlaxoSmithKline

Completed

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Romania, Russian Federation, Ukraine, Germany, Hungary, Bulgaria
GlaxoSmithKline
Optum-data vendor

Completed

Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline
Parexel

Completed

A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Recruiting

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Asthma

United States
GlaxoSmithKline

Recruiting

Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

Asthma

China
GlaxoSmithKline

Completed

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Germany, Poland, Romania, Russian Federation, Ukraine
GlaxoSmithKline

Completed

A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects

Pulmonary Disease, Chronic Obstructive

China
GlaxoSmithKline

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

India
GlaxoSmithKline

Completed

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Chile, Romania, Canada
GlaxoSmithKline

Completed

To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

Pulmonary Disease, Chronic Obstructive

China
GlaxoSmithKline

Completed

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

Pulmonary Disease, Chronic Obstructive

Germany, United States, Korea, Republic of, Czech Republic
GlaxoSmithKline

Completed

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Asthma

Australia, United States, Argentina, Canada, Germany, Japan, Korea, Republic of, Romania, Russian Federation, Spain, South Africa, Netherlands, Poland, Italy, United Kingdom
Dr. Grace Parraga
GlaxoSmithKline

Active, not recruiting

Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma (ETHA)

Asthma

Canada
GlaxoSmithKline

Completed

INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design

Pulmonary Disease, Chronic Obstructive

Germany, Spain, Netherlands, Sweden, United Kingdom
GlaxoSmithKline

Completed

Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Australia, Argentina, Japan, Russian Federation, Spain, Germany, Mexico, Romania, Korea, Republic of, Poland, Italy, France
GlaxoSmithKline
Q2 Solutions; York Bioanalytical Solution; BI Medical.Inc; SRL Mediserch.Inc; Parexel...

Completed

A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma

Asthma

Japan
Novartis

Completed

Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)

Typhoid Fever

Belgium
GlaxoSmithKline
Parexel

Completed

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Poland, United States, Russian Federation
GlaxoSmithKline

Completed

Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium

Pulmonary Disease, Chronic Obstructive

Argentina, Germany, Romania, Russian Federation, Estonia, Peru, Poland, France, Chile, Hungary, Italy, Slovakia
GlaxoSmithKline

Completed

A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

Taiwan, Thailand, China, Philippines, Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects

Bacterial Infections | Typhoid Fever | Salmonella Infections

Japan
GlaxoSmithKline

Completed

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Chile, South Africa, Romania, Mexico, Norway
fan li

Recruiting

Virtual Ileostomy Versus Diverting Ileostomy

Rectal Cancer

China
Istituto Nazionale di Ricovero e Cura per Anziani

Completed

Diagnostic Performance of the Vesical Imaging-Reporting and Data System (VI-RADS) in Detecting Muscle-invasive Bladder Tumour (MIBC) in Clinical Practice: Comparison With Transurethral Resection of Bladder Cancer (TURB) and Evaluation of Diagnostic Accuracy According to Tumour Location (VI-RADS)

Bladder Cancer

Italy
University of Oxford

Completed

Vaccines Against Salmonella Typhi (VAST)

Typhoid Fever | Enteric Fever

United Kingdom
International Centre for Diarrhoeal Disease Research...

Recruiting

Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh

Typhoid

Bangladesh
GlaxoSmithKline

Completed

A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Canada, Germany, Spain, United States, Italy, Netherlands, South Africa, Sweden, France, Mexico, Australia
VA Office of Research and Development
Baylor College of Medicine

Completed

A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making (Aim3)

Chronic Obstructive Pulmonary Disease | Lung Cancer | Chronic Kidney Disease | Cirrhosis | Congestive Heart Failure | Colon Carcinoma

United States
International Vaccine Institute
SK Chemicals Co., Ltd.

Completed

Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine

Typhoid
GlaxoSmithKline
Parexel

Completed

To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)

Asthma

United States
GlaxoSmithKline

Completed

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Puerto Rico, United States, Australia, Argentina, France, Germany, Japan, Netherlands, Russian Federation, Spain, Ukraine, Finland, Czechia, Poland, Belgium, Chile, Peru, South Africa, Sweden, Thailand, Israel, Korea, Republic of, C... and more
Medical University of Graz
CBmed Ges.m.b.H.

Active, not recruiting

Post COVID-19 Syndrome and the Gut-lung Axis

Covid19

Austria
GlaxoSmithKline

Completed

A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Poland, Romania, Russian Federation, Ukraine, Bulgaria, Estonia, Mexico, Korea, Republic of, Slovakia, Greece, China, Italy, Hungary, Czechia
Loewenstein Hospital

Unknown

tDCS and VI to Treat Neuropathic Pain and Function in SCI

SCI - Spinal Cord Injury
GlaxoSmithKline

Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, United States, Netherlands, Czechia
DongGuk University

Completed

Comparison of Endotracheal Intracuff Pressure Between Two Cuff Sealing Methods

Endotracheal Tube

Korea, Republic of
Medigreen Biotechnology Corp.

Unknown

Safety Study of Anti-Asthma Agent BMEC-1217B

Asthma

Taiwan
University of Maryland, Baltimore
Bill and Melinda Gates Foundation; Groupe de Recherche Action en Sante

Completed

Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso

Typhoid

Burkina Faso
PT Bio Farma

Completed

Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants

Safety Issues | Immunogenicity

Indonesia
GlaxoSmithKline

Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Czechia
Novartis

Completed

Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults

Typhoid Fever

Belgium
Weill Medical College of Cornell University
Angiocrine Bioscience

Recruiting

E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Anal Fistula

United States
University of California, San Francisco
National Institute of Mental Health (NIMH)

Completed

Inflammation and Threat Sensitivity in PTSD (K01)

Posttraumatic Stress Disorder

United States
University of California, San Francisco
National Institute of Mental Health (NIMH)

Completed

Cognitive, Emotional, and Neural Responses to Acute Inflammation

Healthy

United States
Novartis

Completed

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)

Typhoid Fever

Belgium
Hospital Sirio-Libanes

Completed

Diaphragm Activity During Incentive Spirometry and Diaphragmatic Breathing

Breathing Exercises | Incentive Spirometry | Diaphragmatic Breathing | Diaphragm Mobility

Brazil
International Vaccine Institute
University of Cambridge; Institute of Tropical Medicine, Belgium; Institut National...

Recruiting

Effectiveness of a Typhoid Conjugate Vaccine in DRC (TyVECO)

Typhoid Fever

Congo, The Democratic Republic of the
University of Maryland, Baltimore
University College, London; Bill and Melinda Gates Foundation; Malawi-Liverpool-Wellcome... and other collaborators

Active, not recruiting

Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi

Typhoid

Malawi

3

Subscribe